MedTrace Logo

Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)

NCT04639375 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2021-08-27

No results posted yet for this study

Summary

A total of 300 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1. Blood specimens collected pre-inoculation will be tested for cross-reactivity to poliovirus and SARS-CoV-2 by Western blot. An additional specimen will be collected on Day 28 post-inoculation and, likewise tested for cross-reactivity to poliovirus and SARS-CoV-2.

The number of subjects with an immune response to SARS-CoV-2 antigens following inoculation with IPV will be summarized.

Conditions

Interventions

BIOLOGICAL

Vaccinated with polio vaccine (IPV)

poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States

Sponsors & Collaborators

  • E-MO Biology Inc

    lead INDUSTRY

Principal Investigators

  • John Andrews · E-MO Biology Inc

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-15
Primary Completion
2021-06-12
Completion
2022-06-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04639375 on ClinicalTrials.gov